Startseite
Kongressberichte 2018
ELCC 2018 (European Lung Cancer Congress)
SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
SAKK 16/14 - Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC).
A multicenter single-arm phase II trial
Sacha I. Rothschild, Alfred Zippelius, Spasenija Savic Prince, Michel Gonzalez, Walter Weder, Alexandros Xyrafas, Corinne Rusterholz, Miklos Pless; on behalf of the Swiss Group for Clinical Cancer Research
 |
POSTER |